NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
Clinical Trials
4 trialsNCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT00724360 2013-10-07
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
Nantes University Hospital
Phase 2 Terminated
NCT00189579 2007-08-17
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated